AUX 101
Latest Information Update: 26 Mar 2007
At a glance
- Originator Auxeris Therapeutics (CEASED)
- Class Osteoporosis therapies
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fracture; Osteoporosis
Most Recent Events
- 27 Aug 2003 Preclinical trials in Fracture in USA (unspecified route)
- 27 Aug 2003 Preclinical trials in Osteoporosis in USA (unspecified route)
- 27 Aug 2003 Preclinical trials in Spinal fusion in USA (unspecified route)